TRIBBLES Research and Innovation Network
TRAIN (Tribbles Research And Innovation Network) brings together a group of leading European scientists working at the interface of the control of energy homeostasis, metabolism and innate immunity to characterise the how the interaction between these physiological systems influences the development of prostate cancer. We will approach this by investigating the consequences of tissue specific loss of tribbles pseudokinases as these proteins have previously been shown to be potent regulators of both energy and immune homeostasis and have also been implicated as important regulators of cancer development.
Our Network will coordinate fifteen highly integrated, interdisciplinary projects, which have the overall aim of gaining clinical/mechanistic insights into the cell-specific metabolic and signalling pathways that both regulate cell proliferation/differentiation decisions made in metabolic tissues, immune cells as well as in prostatic epithelial cells.
TRAIN is coordinated by Dr Endre Kiss-Toth from the University of Sheffield and involves ten academic and industrial partners from UK, Spain, Germany, France, The Netherlands, Portugal and Hungary. It is funded by the EU with a €3.8 million grant under the Marie Sklodowska Curie Innovative Training Network (ITN) programme. This will provide a unique opportunity for a cohort of 15 PhD students to undertake research training at the interface of several disciplines and sectors, thereby gaining a diverse portfolio of R&D expertise and transferrable skills. Individual, multidisciplinary PhD projects enhanced by inter-sectorial secondments, bespoke training programmes and multi-disciplinary supervisory teams will be complemented by dissemination and outreach activities, training in entrepreneurship and patenting skills, as well as exposure to several non-academic career pathways. Our programme will provide a new generation of trained scientists with the skills and knowledge to contribute to a step change in our understanding of the mechanisms driving obesity-related CVD and tumour aggressiveness and thus pave the way for early diagnosis, prevention and the development of innovative, more ‘holistic’ cell-therapies.